System for detecting extracellular purinergic receptor ligands and non-human animals incorporating said system

Genetically modified animals with fusion proteins for purinergic receptor ligands allow non-invasive, systemic detection, addressing the limitations of existing methods and facilitating disease monitoring and therapeutic development.

JP7765290B2Active Publication Date: 2025-11-06CHUGAI PHARMA CO LTD
4 Cites 0 Cited by

Patent Information

Application Number
JP2021564063
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-13
Filing Date
2020-12-11
Publication Date
2025-11-06
Estimated Expiration
2040-12-11

AI Technical Summary

Technical Problem

Existing methods struggle to detect extracellular purinergic receptor ligands systemically, minimally invasively, and in a time-dependent manner, making it difficult to evaluate their role in diseases and develop therapeutic agents effectively.

Method used

Genetically modified non-human animals expressing fusion proteins, such as split luciferase or split fluorescent proteins, that reconstitute upon binding to extracellular purinergic receptor ligands, allowing non-invasive, systemic, and time-dependent detection and quantification of these ligands.

Benefits of technology

Enables non-invasive, systemic detection of extracellular purinergic receptor ligands, facilitating disease monitoring and therapeutic agent development by identifying disease onset sites and timing, and screening for effective treatments.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The purpose of the present invention is to provide an evaluation system that enables less invasive, over-time and systemic detection of an extracellular purinergic receptor ligand. Provided is a transgenic nonhuman animal that expresses a first fused protein and a second fused protein for detecting a purinergic receptor ligand present outside cells, wherein the first fused protein contains a membrane protein capable of binding to the purinergic receptor ligand and a first reporter protein and the second fused protein contains a protein capable of binding to the membrane protein to which the ligand is bound and a second reporter protein. Also provided is a cell of the transgenic nonhuman animal.
Need to check novelty before this filing date? Find Prior Art